Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Atea Pharmaceuticals, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- 0 vs. Q2 2022
- Shares held
- 57.4M
- −64.0K (−0.1%) vs. Q2 2022
- Total value
- $326.8M
- −$81.9M (−20.0%) vs. Q2 2022
- New holders
- 15
- 50 more added
- Sold out
- 15
- 34 more reduced
2 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVIR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 124 | $276.4M |
| Q1 2026 | 127 | $322.8M |
| Q4 2025 | 111 | $203.5M |
| Q3 2025 | 115 | $154.2M |
| Q2 2025 | 107 | $189.7M |
| Q1 2025 | 104 | $158.3M |
| Q4 2024 | 107 | $188.7M |
| Q3 2024 | 108 | $194.0M |
| Q2 2024 | 105 | $187.7M |
| Q1 2024 | 113 | $219.6M |
| Q4 2023 | 108 | $168.3M |
| Q3 2023 | 119 | $170.6M |
| Q2 2023 | 133 | $213.3M |
| Q1 2023 | 131 | $190.2M |
| Q4 2022 | 131 | $278.1M |
| Q3 2022 | 126 | $326.8M |
| Q2 2022 | 128 | $408.7M |
| Q1 2022 | 127 | $396.6M |
| Q4 2021 | 143 | $479.2M |
| Q3 2021 | 142 | $1.99B |
| Q2 2021 | 104 | $1.27B |
| Q1 2021 | 82 | $3.20B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Atea Pharmaceuticals, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CM Management, LLC | 250,000 | $1.42M | 1.59% | +50,000+25.0% | Added |
| Jupiter Asset Management Ltd | 263,056 | $1.50M | 0.02% | 00.0% | Unchanged |
| Citadel Advisors LLC | 292,804 | $1.67M | 0.00% | +33,750+13.0% | Added |
| Prudential Financial Inc | 294,635 | $1.68M | 0.00% | −84,700−22.3% | Reduced |
| Bank of New York Mellon Corp | 306,856 | $1.75M | 0.00% | +36,812+13.6% | Added |
| Banque Pictet & Cie SA | 345,077 | $1.96M | 0.02% | 00.0% | Unchanged |
| Nuveen Asset Management, LLC | 347,923 | $1.98M | 0.00% | +77,760+28.8% | Added |
| Bridgeway Capital Management, LLC | 355,612 | $2.02M | 0.05% | +8,000+2.3% | Added |
| Ally Bridge Group (NY) LLC | 360,000 | $2.05M | 1.35% | +360,000 | New |
| Jacobs Levy Equity Management, Inc | 380,517 | $2.17M | 0.02% | −51,921−12.0% | Reduced |
| Morgan Stanley | 496,980 | $2.83M | 0.00% | +104,464+26.6% | Added |
| Charles Schwab Investment Management Inc | 553,324 | $3.15M | 0.00% | +125,603+29.4% | Added |
| Renaissance Technologies LLC | 597,400 | $3.40M | 0.00% | −65,600−9.9% | Reduced |
| K2 Principal Fund, L.P. | 605,419 | $3.44M | 0.83% | −1,000,640−62.3% | Reduced |
| Northern Trust Corp | 725,226 | $4.13M | 0.00% | +32,100+4.6% | Added |
| Balyasny Asset Management LLC | 751,073 | $4.27M | 0.02% | −1,048,434−58.3% | Reduced |
| Acadian Asset Management LLC | 825,763 | $4.70M | 0.03% | +111,341+15.6% | Added |
| Geode Capital Management, LLC | 1,389,203 | $7.90M | 0.00% | +227,779+19.6% | Added |
| Cormorant Asset Management, LP | 1,547,181 | $8.80M | 0.62% | 00.0% | Unchanged |
| State Street Corp | 1,894,736 | $10.8M | 0.00% | +91,368+5.1% | Added |
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $14.1M | 1.69% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 3,626,818 | $20.6M | 0.06% | +38,687+1.1% | Added |
| EcoR1 Capital, LLC | 6,184,861 | $35.2M | 1.04% | −155,778−2.5% | Reduced |
| Vanguard Group Inc | 7,584,256 | $43.2M | 0.00% | +403,971+5.6% | Added |
| BlackRock Inc. | 7,871,121 | $44.8M | 0.00% | +463,579+6.3% | Added |
| FMR LLC | 12,488,746 | $71.1M | 0.01% | −50,729−0.4% | Reduced |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −265,365−100.0% | Sold out |
| Privium Fund Management (UK) Ltd | 0 | $0 | 0.00% | −61,284−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −60,067−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −30,911−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −26,656−100.0% | Sold out |
| Wexford Capital LP | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −25,080−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −23,032−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −21,800−100.0% | Sold out |
| Blair William & Co | 0 | $0 | 0.00% | −14,439−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −10,878−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −10,196−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| South State Corp. | 0 | $0 | 0.00% | −565−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −502−100.0% | Sold out |
| Private Capital Group, LLC | – | – | – | – | Not filed |
| Exane Derivatives | – | – | – | – | Not filed |